Blueprint Genetics and ARCHIMEDlife form a partnership to launch high-quality biochemical testing for rare diseases in North America

September 24, 2019

Combining high-quality biochemical testing with innovative genetic testing forms a powerful tool for personalized medicine, clinical research, and diagnostics in rare diseases.

ARCHIMEDlife Medical Laboratory, based in Vienna, provides biochemical and genetic testing for rare diseases, ranging from inborn errors of metabolism to endocrinology and beyond. Blueprint Genetics, based in Helsinki and Seattle, provides clinical genetic testing to healthcare professionals and university hospitals worldwide, with a focus on rare inherited diseases in 14 medical specialties.

Through the collaboration, the two companies will have the potential to provide a wide range of testing services in genetic disorders for North American customers, including clinical mass spectrometry and next-generation sequencing. Biomarker and confirmatory genetic testing can be easily performed for adults and children using dried blood spots as a collection tool, which only requires a few blood drops from a fingertip or newborn’s heel. The combined testing services will be available in early 2020.

“Our combined global presence and experience in the field allows us to pursue very interesting opportunities together in the North American rare disease space. I am excited to see our new combined offering in biomarker testing rolled out with ARCHIMEDlife,” said Blueprint Genetics CEO Tommi Lehtonen.

“The vision of ARCHIMEDlife was to combine both cutting-edge technologies in diagnostic services with clinical experience and knowing exactly the clinical needs of physicians to provide specialized diagnostics for their patients. Now we have the opportunity, together with a powerful and growing genetic testing company, to serve North American customers. This unique partnership with the combination of clinical background, laboratory medicine and innovation will open and accelerate diagnostic testing including biomarkers, making them accessible to patients,” said ARCHIMEDlife CEO and founder David Kasper.

As a result, Blueprint Genetics will be offering next-generation sequencing (NGS) tests for single gene, panel and clinical whole exome sequencing (WES), combined with biochemical tests to collaborate with physicians, clinical researchers and industry specialized in personalized health care in order to provide rare disease patients a faster, earlier diagnosis.

ARCHIMEDlife is an innovative and dynamic Medical Laboratory providing high quality, specialized diagnostic services for Rare Diseases and more, located in Vienna, Austria. The company is committed to helping physicians and their patients avoid diagnostic odysseys by delivering novel, leading-edge, rapid services. ARCHIMEDlife is also working with prominent pharmaceutical companies in the orphan drug market to further these objectives. Since its establishment in 2013, more than 20,000 physicians in 75 countries have trusted in their services.

Blueprint Genetics is one of the fastest-growing genetic testing businesses globally in the field of clinical genetic testing of rare inherited diseases. With a patient-centered mindset, the company was founded in 2012 and has since been on a mission to bring world-class genetic knowledge to mainstream healthcare with four guiding principles: innovation, transparency, quality and accessibility. The company is based in Helsinki and Seattle, with a customer base spanning over 70 countries. 

Further information
Blueprint Genetics

Tommi Lehtonen, CEO,
Juulia Simonen, Communication Manager,, +358 50 305 9018


David Kasper, CEO,


Subscribe to our press releases